Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Ross

Showing results (1-10 of 130) with videos related to

Pageof 13
Sort By:
The Lancet. Oncology|May 9, 2018
Chronic myeloid leukaemia: going off pisteDavid M Ross
British Journal of Haematology|April 20, 2021
How much imatinib is enough?David M Ross
Leukemia & Lymphoma|April 18, 2009
Extramedullary relapse of chronic myeloid leukemia in blast crisis: more questions than answersDavid M Ross
Leukemia & Lymphoma|January 5, 2026
Prediction of relapse after discontinuation of tyrosine kinase inhibitor treatment in CMLDavid M Ross
The Lancet. Haematology|December 22, 2015
Treatment-free remission after stopping second-line dasatinibDavid M Ross
British Journal of Haematology|February 11, 2022
Iron chelation for myelofibrosis-related anaemia during treatment with a Janus kinase inhibitorDavid M Ross
Blood|June 1, 2023
Single cells tell multiple tales in CMLDavid M Ross
Leukemia & Lymphoma|May 27, 2011
Minimal residual disease: the advantages of digital over analog polymerase chain reactionDavid M Ross, Susan Branford
Blood|March 1, 2013
Giant parallel tubular arrays in T lymphocytesDavid M Ross, John Stirling
British Journal of Haematology|November 10, 2020
Counterpoint: There is a best duration of deep molecular response for treatment-free remission, but it is patient-specific, and that is the challengeDavid M Ross, Timothy P Hughes
Pageof 13

Showing results (1-10 of 130) with videos related to

Sort By:
Pageof 13
The Lancet. Oncology|May 9, 2018
Chronic myeloid leukaemia: going off pisteDavid M Ross
British Journal of Haematology|April 20, 2021
How much imatinib is enough?David M Ross
Leukemia & Lymphoma|April 18, 2009
Extramedullary relapse of chronic myeloid leukemia in blast crisis: more questions than answersDavid M Ross
Leukemia & Lymphoma|January 5, 2026
Prediction of relapse after discontinuation of tyrosine kinase inhibitor treatment in CMLDavid M Ross
The Lancet. Haematology|December 22, 2015
Treatment-free remission after stopping second-line dasatinibDavid M Ross
British Journal of Haematology|February 11, 2022
Iron chelation for myelofibrosis-related anaemia during treatment with a Janus kinase inhibitorDavid M Ross
Blood|June 1, 2023
Single cells tell multiple tales in CMLDavid M Ross
Leukemia & Lymphoma|May 27, 2011
Minimal residual disease: the advantages of digital over analog polymerase chain reactionDavid M Ross, Susan Branford
Blood|March 1, 2013
Giant parallel tubular arrays in T lymphocytesDavid M Ross, John Stirling
British Journal of Haematology|November 10, 2020
Counterpoint: There is a best duration of deep molecular response for treatment-free remission, but it is patient-specific, and that is the challengeDavid M Ross, Timothy P Hughes
Pageof 13